Contraceptives Market - By Product (Devices (Condoms, Intra-uterine Devices), Drugs (Oral Contraceptive Pills)), Age Group (15 - 44 Years, Above 44 Years), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Channels) & Forecast, 2024 – 2032

Contraceptives Market Size

Contraceptives Market size was valued at USD 23 billion in 2023 and is expected to exhibit growth at a CAGR of 6.3% from 2024 to 2032. High market growth can be attributed to increasing emphasis on prevention of sexually transmitted diseases, growing awareness about new technologies for pregnancy prevention, and awareness programs for sexual wellness.
 

The market growth is further attributed to the growing awareness of reproductive health and family planning. Governments, NGOs, and healthcare organizations have been actively promoting contraceptive use as part of broader health initiatives aimed at reducing unplanned pregnancies and improving maternal health. Educational campaigns, both in schools and through the media, are helping to spread knowledge about the importance of contraception. This growing awareness is particularly evident in both developed and developing countries, where increased access to information and healthcare services has resulted in higher adoption rates of contraceptives across various demographics.
 

In addition, many countries are implementing policies that provide free or subsidized contraceptives through national healthcare systems, particularly targeting low-income populations. Programs like the Affordable Care Act (ACA) in the U.S., the NHS in the UK, and public health initiatives in countries like India and Brazil have significantly improved access to contraceptive options. Moreover, governments are investing in infrastructure to support family planning education, further facilitating access to a wide range of contraceptive methods, thereby contributing to market growth.
 

Contraceptives refer to a range of medical devices, drugs, and products designed to prevent pregnancy. These products work by inhibiting ovulation, blocking sperm, or creating an unfavorable environment for fertilization. Contraceptive options include oral pills, intrauterine devices (IUDs), condoms, and hormonal patches. They are widely used to control birth rates, support family planning efforts, and provide individuals and couples with greater control over their reproductive health.
 

Contraceptives Market Trends

The increasing demand for long-acting reversible contraceptives (LARCs), such as IUDs and contraceptive implants, has emerged as a prominent trend due to their high efficacy and long-term protection. LARCs are gaining popularity because they require minimal maintenance and are preferred by women seeking longer-term solutions for birth control.
 

• Additionally, the rising popularity of over-the-counter contraceptives, such as condoms and emergency contraceptive pills, is boosting market growth, driven by ease of access and affordability. The rise of digital health platforms offering online consultations and prescription services for contraceptives is also reshaping the distribution landscape, providing users with convenient, remote access to birth control.
   
• Another significant trend influencing the market is the increasing focus on male contraceptives. Research and development in male contraceptive options, including hormonal and non-hormonal methods, are progressing, with several products currently in clinical trials. This diversification in contraceptive options is likely to create new opportunities in the market. Additionally, growing awareness of environmental sustainability has led to a rise in demand for eco-friendly and biodegradable contraceptive products, further shaping market preferences.
   

Contraceptives Market Analysis

Based on product, the market is classified into drugs and devices. The devices segment generated the highest revenue of USD 16 billion in 2023.
 

• Devices such as intrauterine devices (IUDs), contraceptive implants, and vaginal rings provide prolonged protection, often lasting several years without requiring daily or monthly attention. This reliability and ease of use make them appealing to women seeking consistent and low-maintenance birth control. IUDs, for example, are among the most effective forms of contraception, with a failure rate of less than 1%, providing a high level of confidence for users.
   
• Furthermore, the growing awareness of the benefits of non-hormonal contraceptive devices, such as copper IUDs, has expanded the market. These devices cater to women who prefer to avoid hormonal side effects, offering a viable alternative while maintaining high efficacy. The increasing availability of different device options in healthcare settings, along with rising government initiatives promoting LARCs, has further propelled the market for contraceptive devices.
   

Based on age group, the contraceptives market is categorized into 15-44 years and above 44 years. The 15-44 years segment generated the highest revenue of USD 21.3 billion in 2023.
 

• The age group 15-44 years dominated the market, as this is the most fertile and sexually active demographic, making contraception a critical aspect of their reproductive health management. Individuals in this age group are more likely to be concerned about preventing unwanted pregnancies while planning for family-building later in life. With increasing awareness about family planning and sexual health, there is a higher adoption rate of contraceptives among individuals within this age group.
   
• Further, gradual shift in socio-cultural dynamics, with more women focusing on careers and delaying childbearing are also one of the prominent factors for segment growth. This has increased the use of contraceptive methods to manage reproductive health and plan pregnancies according to personal and professional goals. Healthcare providers and government bodies also target this age group for family planning initiatives and contraceptive distribution programs, increasing access to birth control products.
   

Based on distribution channel, the contraceptives market is segmented into retail pharmacies, hospital pharmacies, online channels, and other distribution channels. The retail segment dominated the market in 2023 and is anticipated to reach USD 18.3 billion by the end of the forecast period.
 

• Consumers find retail pharmacies to be convenient sources for purchasing contraceptives, including over-the-counter products such as condoms and emergency contraceptive pills. The availability of contraceptive drugs, such as oral pills and patches, at retail pharmacies further drives their dominance in the market. Many consumers prefer retail pharmacies for the ease of access, consultation with pharmacists, and the ability to purchase products without the need for a doctor's appointment.
   
• In addition, retail pharmacies have expanded their product offerings to include a variety of contraceptive products, both prescription-based and non-prescription. This variety allows consumers to explore different options based on their preferences and needs. The growth of chain pharmacies and the presence of dedicated health sections in major retail stores also contribute to the increased market share of this segment.
   

North America contraceptives market accounted for USD 7.5 billion market revenue in 2023 and is anticipated to grow at a CAGR of 4% between 2024 and 2032.
 

• The contraceptive market in North America is growing due to rising awareness of family planning and reproductive health, supported by government initiatives and healthcare policies. In countries like Canada, access to contraceptive products is widely available through both public and private healthcare systems. Educational campaigns focused on sexual health also contribute to higher adoption rates, particularly among younger women.
   
• In addition, increasing demand for long-acting reversible contraceptives (LARCs) like IUDs has also driven the contraceptive market in North America. The healthcare system's support for family planning services, combined with a growing number of clinics and providers offering affordable contraceptive options, enhances accessibility.
   

U.S. contraceptives market accounted for USD 7.2 billion market revenue in 2023 and is estimated to hold substantial share between 2024 and 2032.
 

• The growth of the U.S. contraceptive market is growing due to increasing awareness of sexual health and reproductive rights. The Affordable Care Act (ACA) has played a significant role in expanding access to contraceptives, particularly by providing insurance coverage for various birth control methods. This has encouraged women across different age groups to explore contraception as part of their healthcare routine.
   
• Moreover, the market has experienced significant growth due to increasing demand for innovative contraceptive products, such as extended-release contraceptives and implants. For instance, the FDA in July 2023 approved the first non-prescription daily oral contraceptive in the U.S., developed by Perrigo Company plc. This milestone reflects broader industry efforts, as manufacturers are heavily investing in research and development to introduce more convenient and less invasive contraceptive options, thereby improving accessibility to safe and effective birth control for a wider population.
   

UK contraceptives market is projected to grow substantially in the coming years.
 

• The contraceptive market in the UK is driven by the National Health Service's (NHS) comprehensive birth control offerings, which provide free access to various contraceptive methods. The government's proactive stance on family planning and its support for reproductive health have contributed to high adoption rates. Public health campaigns on safe sex and contraception further fuel demand, especially among younger women.
   
• In addition, the UK's focus on promoting LARCs, such as IUDs and contraceptive implants, has significantly impacted the market. The rising demand for long-term contraceptive methods, coupled with the availability of newer options, has driven growth in the contraceptive market in the UK.
   

Japan holds a dominant position in the Asia Pacific contraceptives market.
 

• Japan’s contraceptive market is relatively small compared to Western countries, but it has seen steady growth in recent years due to changing social attitudes toward family planning and increased awareness about reproductive health. The government has introduced educational programs to raise awareness of contraception among the younger population, which has led to a gradual increase in adoption rates. In Japan, oral contraceptives and condoms are the most popular methods of birth control, largely due to their ease of use and cultural acceptance.
   
• The growing influence of Western family planning methods, along with greater availability of contraceptive products, has also contributed to the market’s expansion. Additionally, Japan has seen a rise in demand for emergency contraceptive pills, especially among younger women, further contributing to the growth of the contraceptive market in the country.
   

Contraceptives Market Share

Major players in the market are investing in research and development to introduce innovative products. Key developments include the launch of non-hormonal contraceptives, advancements in contraceptive delivery systems, and collaborations to enhance access to contraceptive products in underserved regions. For example, partnerships between pharmaceutical companies and non-governmental organizations are helping to expand the reach of affordable contraceptives in low-income countries.
 

Contraceptives Market Companies

Prominent players operating in the contraceptives industry include:

• Afaxys, Inc.
• Agile Therapeutics
• Amneal Pharmaceuticals
• Bayer AG
• Church & Dwight Co., Inc.
• Cooper Companies
• Evofem Biosciences
• HRA Pharma
• Maxwellia Ltd
• Mayer Laboratories, Inc.
• Mithra Pharmaceuticals
• Organon & Co.
• Pfizer, Inc.
• Reckitt Benckiser Group PLC
• TherapeuticsMD, Inc.
• Veru, Inc.
   

Contraceptives Industry News:

• In February 2021, Amneal Pharmaceuticals, Inc. received FDA approval for its generic version of Ortho Evra. The newly launched patch is prescribed for the prevention of pregnancy. This approval not only enhances Amneal Pharmaceuticals product portfolio but also reinforces their position in the contraceptive market by offering a cost-effective alternative to branded options.
   
• In October 2023, Xiromed LLC announced launch of its new vaginal ring, called as EnilloRing in the U.S. market. The newly launched product is generic version of Nuvaring. The introduction of EnilloRing allows Xiromed LLC to capitalize on the demand for affordable contraceptive solutions, further expanding their footprint in the U.S. market.
   

The contraceptives market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

By Product

• Devices
  • Condoms
    • Male
    • Female
  • Intra-uterine devices
    • Hormonal IUD
    • Copper IUD
  • Vaginal rings
  • Subdermal implants
  • Diaphragms
  • Contraceptive sponges
• Drugs
  • Oral contraceptive pills
  • Injectable contraceptives
  • Topical contraceptives

By Age Group

• 15 - 44 years
• Above 44 years

By Distribution Channels

• Retail pharmacies
• Hospital pharmacies
• Online channels
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa